Skip to main content
Log in

RETRACTED ARTICLE: Utilization of solid in oil nanodispersion to prepare a topical vemurafenib as potential delivery system for skin melanoma

  • Original Article
  • Published:
Applied Nanoscience Aims and scope Submit manuscript

This article was retracted on 10 January 2024

This article has been updated

Abstract

Vemurafenib (VEM) is a recently licensed chemotherapeutic medication for the treatment of melanoma. Since the medicine is frequently taken orally, it can easily cause damage to important organs as well as to its low absorption. In this work, solid in oil nanodispersion (SON) was adapted to prepare a topical vemurafenib to target skin melanoma at early stages. SON is a unique oil-based dispersion that has been developed for revolutionary medication delivery methods. Both hydrophilic and hydrophobic bioactive drugs have the potential to be carried and delivered by this system. In our method, water and cyclohexane were removed from the W/O emulsion precursor containing 100 mg VEM by lyophilization, followed by redispersion of the surfactant–drug complex in another oil carrier, isopropyl myristate (IPM) to adjust VEM concentration (10 mg/ml). High energy techniques were used to produce VEM as SONs, with sucrose fatty acid ester surfactant (sucrose monolaurate, L195) in various ratios, as well as control was prepared by dispersing pure VEM in IPM (10 mg/ml). The preparations were evaluated for in vitro release through dialysis bag and ex vivo permeation experiments through Albino Wistar rat abdomen skin to simulate human skin as well as particle size, pH, partition coefficient, and entrapment efficiency. SON formula containing VEM-L195 complex in the ratio of 1:6.6 (F3) shows acceptable partition coefficient (Log P > 1), pH values appropriate for skin melanoma application, acceptable particle sizes, and good VEM entrapment efficiency. F3 was found to be released in vitro in a sustained pattern (9% in 1 h and 100% after 24 h) through the dialysis membrane compared to the control (25.9% in 1 h and 95.8% after 24 h). Ex vivo VEM permeability through rat abdomen skin was considerably (P < 0.05) higher for SON-F3 versus control (72% and 29%, respectively). Such SON formulation could be able to deliver VEM topically in an effective, sustained, and safe manner to treat early diagnosed skin melanoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Change history

References

Download references

Acknowledgements

The authors would like to thank Mustansiriyah University, Baghdad/Iraq (www. uomustansiriyah. edu. iq) for supporting this work.

Funding

No funding by yourself supported.

Author information

Authors and Affiliations

Authors

Contributions

All the authors have contributed equally.

Corresponding author

Correspondence to Yasir Q. Almajidi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article has been retracted. Please see the retraction notice for more detail:https://doi.org/10.1007/s13204-024-03024-3

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Almajidi, Y.Q., Maraie, N.K. & Raauf, A.M.R. RETRACTED ARTICLE: Utilization of solid in oil nanodispersion to prepare a topical vemurafenib as potential delivery system for skin melanoma. Appl Nanosci 13, 2845–2856 (2023). https://doi.org/10.1007/s13204-021-02158-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13204-021-02158-y

Keywords

Navigation